Navigation Links
Haemacure Announces Preliminary Findings of its Plasma Discard,Analysis

proteins and enzymes cannot be realized without FDA approval. Haemacure will continue identification work on its plasma discard and seek partnerships with pharmaceutical and biotechnology companies that would fund the development and clinical activities required to bring these proteins and enzymes to market and with which it would share sales revenues.

About Haemacure

Haemacure Corporation is a specialty biotherapeutics company focused on developing and commercializing premium human therapeutic proteins. Haemacure utilizes its proprietary plasma protein extraction technology to develop next generation products, including hemostats for surgical use. Haemacure's lead product candidate, Hemaseel(TM)HMN, an all-human fibrin sealant, is in late stage clinical development for biosurgical applications. The second product, an all-human thrombin, a component of fibrin sealant, also has applications as a stand-alone product in the expanding biosurgical market. Follow-on development will focus on biomaterial combinations and drug delivery in select therapeutic areas. Haemacure will develop partnerships to advance specialty proteins that it has recently identified in its plasma-derived intermediates to address the unmet medical needs of patients. Haemacure also operates offices in Sarasota, Florida through a wholly-owned subsidiary. The Corporation is traded under stock symbol HAE on the TSX.

Forward-looking Statements

Certain of the statements contained in this news release are forward-looking statements. Such statements, based as they are on the current expectations of management, inherently involve numerous risks and uncertainties, known and unknown. Some examples of known risks are: the impact of general economic conditions, general conditions in the biotech industry, changes in the regulatory environment in the jurisdictions in which Haemacure Corporation does business, stock market volatility, fluctuations in costs, and changes to the competit
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
2. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
3. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
4. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
5. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
8. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
9. Protox Announces Positive Clinical Data from Prostate Cancer Study
10. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
11. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
Post Your Comments:
(Date:10/22/2014)... and AUSTIN, Texas , ... PureMHC LLC today announced they have entered into ... antibody-based immunotherapies designed to target cancers. ... peptides displayed on the surfaces of tumor cells ... targets (PTTs), derived from proteins that play a ...
(Date:10/22/2014)... and SHANGHAI , Oct. 22, 2014 ... FMI ) and WuXi PharmaTech (Cayman) Inc. (NYSE: ... offer Foundation Medicine,s comprehensive genomic profiling to biopharmaceutical companies ... Under the terms of the collaboration, ... the laboratory component of Foundation Medicine,s FoundationOne® assay at ...
(Date:10/20/2014)... Oct. 20, 2014  ResMed (NYSE: ... ResMed Data Exchange program, a comprehensive suite of ... (HME) and other health care providers. ... to critical patient information. It integrates valuable sleep ... U-Sleep™ patient management platforms with customers, in-house or ...
Breaking Medicine Technology:Biotech Companies To Co-Discover And Co-Develop Antibodies Targeting Novel Phosphopeptide Tumor Targets 2Foundation Medicine and WuXi PharmaTech Announce Strategic Collaboration to Offer Best-in-Class Comprehensive Genomic Profiling in China 2Foundation Medicine and WuXi PharmaTech Announce Strategic Collaboration to Offer Best-in-Class Comprehensive Genomic Profiling in China 3Foundation Medicine and WuXi PharmaTech Announce Strategic Collaboration to Offer Best-in-Class Comprehensive Genomic Profiling in China 4Foundation Medicine and WuXi PharmaTech Announce Strategic Collaboration to Offer Best-in-Class Comprehensive Genomic Profiling in China 5ResMed Launches ResMed Data Exchange 2
... THE WOODLANDS, Texas, Sept. 30, 2011 David, a ... grandfather, felt too young to be diagnosed with prostate ... symptoms." David, under the advisement of his oncologist, decided ... first in a new therapeutic class known as autologous ...
... 30, 2011 The CyberKnife Coalition announced ... CyberKnife Robotic Radiosurgery System® have now been enrolled in ... prostate cancer patients treated with stereotactic body ... (RPCR), tracks clinical and functional outcomes of men with ...
Cached Medicine Technology:The US Oncology Network Affiliated Physicians at Forefront of Cutting-Edge Prostate Cancer Treatment 2The US Oncology Network Affiliated Physicians at Forefront of Cutting-Edge Prostate Cancer Treatment 3The US Oncology Network Affiliated Physicians at Forefront of Cutting-Edge Prostate Cancer Treatment 4First Prostate Cancer Registry for Robotic Radiosurgery Patients Enrolls More than 500 Men 2
(Date:10/22/2014)... October 22, 2014 Hay House is pleased ... Addiction and Upgrade Your Life (Paperback; $10.82) written by the ... & Recovery. This book is meant to help readers ... life of recovery. , Recovery 2.0 is not the ... Recovery 2.0 is a guide for what comes next. ...
(Date:10/22/2014)... 22, 2014 Healthcare professionals who ... continuing education at home or on-the-go via laptops, ... 20 brand new, premium Seminar-on-Demand CE courses. The ... over 2,000 hours of CE course ... educational experience. With such a diverse library, there’s ...
(Date:10/22/2014)... 2014 Richard Carlson, Managing Partner of ... with over 25 years experience. Mr. Carlson is ... areas related to EDI, B2B Commerce, RFID and Internet/Intranet ... Advisory Board member for Pharmaceutical Commerce Magazine and a ... Group is a management and technology consulting firm focused ...
(Date:10/22/2014)... sisters in high school have developed ways to measure ... use electronic stethoscopes, which electronically amplify body sounds, to ... heartbeats. Ilina, a senior at Port Huron Northern ... to detect early lung damage in people exposed to ... one breath cycle each from 16 smokers, 25 nonsmokers ...
(Date:10/22/2014)... HealthDay Reporter , MONDAY, Oct. 20, 2014 (HealthDay ... for health workers treating Ebola patients, now requiring full body ... at all times. The U.S. Centers for Disease Control ... Dallas nurses contracted Ebola while caring for the first ... Duncan. Nina Pham is currently being treated for her infection ...
Breaking Medicine News(10 mins):Health News:Hay House Announces The Official Release of Recovery 2.0: Move Beyond Addiction and Upgrade Your Life 2Health News:Hay House Announces The Official Release of Recovery 2.0: Move Beyond Addiction and Upgrade Your Life 3Health News:Top Provider of Continuing Education at Home Releases 20 New Online Courses 2Health News:Rich Carlson and Marc Duey to Hold Workshop at CBI’s Specialty Pharmacy and Distribution Networks Conference 2Health News:Teen Sisters Develop Ways to Measure Lung, Heart Damage 2Health News:CDC Tightens Rules on Caring for Ebola Patients 2Health News:CDC Tightens Rules on Caring for Ebola Patients 3
... by the Food & Drug Administration for the treatment of prostate ... A new study shows abiraterone acetate extends the lives of ... four months. The study in the May 26, 2011 issue of ... Thomas W. Flaig, MD, medical oncologist at the University of Colorado ...
... Calif. A woman,s risk of developing diabetes during pregnancy ... pregnant based on routinely assessed measures of blood sugar and ... the online issue of the American Journal of Obstetrics ... Kaiser Permanente Division of Research in Oakland, Calif., studied 580 ...
... traumatic stress with war-afflicted populations (veterans and civilians) and ... research professor in the department of psychology and the ... the University of Houston (UH), decided to study another ... eighth grade. "Teaching is a highly stressful ...
... , WEDNESDAY, May 25 (HealthDay News) -- Taken in ... the cholesterol-lowering medication Pravachol, appear to significantly raise blood ... is most apparent -- and concerning -- among diabetics, ... noted. "This interaction may affect as many as ...
... field, poised to take a crucial penalty kick, "I always had a ... do" says sports psychologist Antonis Hatzigeorgiadis. "I was setting the ball and ... of shots; then I had that thought striking me that it was ... he recalls, "and I did miss." Even then, he could see that ...
... Medications are the mainstay of treatment for epilepsy, but for ... many as 1 million in the U.S. drugs don,t ... as refractory or drug-resistant epilepsy, in which drugs can,t control ... last month, Dr. Christopher DeGiorgio, a UCLA professor of neurology, ...
Cached Medicine News:Health News:New drug treatment extends lives of men with prostate cancer 2Health News:Diabetes can be predicted 7 years before pregnancy with blood sugar and body weight 2Health News:New University of Houston research study links job stress in teachers to student achievement 2Health News:New University of Houston research study links job stress in teachers to student achievement 3Health News:Combo of Paxil, Pravachol May Raise Blood Sugar 2Health News:Combo of Paxil, Pravachol May Raise Blood Sugar 3Health News:Thoughts that win 2Health News:Unique nerve-stimulation treatment proves effective against drug-resistant epilepsy 2
The Optima III line of laparoscopic hand instruments provides a well-crafted set of instruments designed for strength and durability....
The Optima III line of laparoscopic hand instruments provides a well-crafted set of instruments designed for strength and durability....
The Optima III line of laparoscopic hand instruments provides a well-crafted set of instruments designed for strength and durability....
Inquire...
Medicine Products: